Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

June 30, 2009

Study Completion Date

September 30, 2009

Conditions
Healthy Subjects
Interventions
DRUG

Ketamine

Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes

DRUG

Nicotine

Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)

DRUG

Placebo

Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes

DRUG

Ketamine and Nicotine

"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"

Trial Locations (1)

06516

Veterans Administration Hospital, West Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT00690170 - Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects | Biotech Hunter | Biotech Hunter